Plain-English translation of NCT07264647 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of chemotherapy and an immunotherapy drug called given before surgery in people with stage III non-small cell lung cancer. The goal is to shrink tumors and reduce lymph node involvement before surgery, and then give the medication for one year afterward to help prevent the cancer from returning. This approach combines the strengths of two different ways to fight cancer: chemotherapy, which directly kills cancer cells, and immunotherapy, which helps your body's immune system recognize and attack cancer.
Stage III lung cancer is advanced and difficult to treat with surgery alone. Researchers believe that giving the medication before surgery may help shrink tumors and make surgery more effective, potentially improving survival and quality of life for patients.
You likely qualify if…
You likely don't qualify if…
You will receive three cycles of chemotherapy combined with the immunotherapy medication, given on a standard schedule. During this time, you'll have imaging scans (CT and PET-CT) and biopsies to see how well the treatment is working. After the three cycles, if your lymph nodes show significant improvement, you'll move forward to surgery followed by one year of maintenance immunotherapy. If your lymph nodes haven't improved enough, you'll receive radiation therapy combined with chemotherapy instead, followed by the same year of immunotherapy maintenance.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Italy